Takeda has officially terminated its neuro partnership with Denali Therapeutics, returning the investigational therapy DNL593, aimed at treating frontotemporal dementia-granulin (FTD-GRN), back to Denali. This decision, disclosed in a recent SEC filing, comes amid Takeda’s extensive restructuring efforts that include significant layoffs, with the company aiming to save approximately $1.26 billion by 2028. The partnership initially formed in 2018 involved co-developing multiple drugs for neurodegenerative diseases, but setbacks, including unfavorable FDA feedback on clinical plans, led to the dissolution of these assets.

The return of DNL593 is strategically motivated, with no reported safety or efficacy concerns influencing Takeda’s decision. Denali intends to advance DNL593 independently and has provided assurances regarding its ongoing phase 1/2 trial, which includes 85 participants, 40 of whom have FTD-GRN. Early results indicate that DNL593 can effectively penetrate the brain without serious safety issues. This is particularly significant as there are currently no approved therapies available to slow the progression of FTD-GRN, highlighting a critical gap in treatment options for this patient population.

The implication of this development is twofold. For Denali, regaining full control over DNL593 allows for a renewed focus on its clinical development timeline, with results expected by the end of 2026. For the broader field of neurodegenerative disease research, this shift underscores the challenges of navigating regulatory landscapes and the importance of strategic partnerships. As Takeda restructures, the industry may see a recalibration of priorities and resources, potentially impacting future collaborations and drug development timelines in neurodegeneration.

Source: fiercebiotech.com